Liu X, Luo J W, Zhou Z M, Wu R Y, Zhang Y, Wang K, Chen X S, Qu Y, Huang X D, Wang X, Bi N, Feng Q F, Lyu J M, Chen D F, Xiao Z F, Xiao J P, Yi J L, Gao L
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2022 Oct 23;44(10):1125-1131. doi: 10.3760/cma.j.cn112152-20201015-00905.
To evaluate the long-term outcomes, failure patterns and prognostic factors of definitive radiotherapy in patients with cervical esophageal carcinoma (CEC). We retrospectively reviewed the clinical data of 148 CEC patients who treated with definitive radiotherapy in Cancer Hospital of Chinese Academy of Medical Sciences from January 2001 to December 2017. The median radiation dose was 66 Gy (59.4-70 Gy) and 33.1% of patients received concurrent chemotherapy. The Kaplan-Meier method was used to calculate survival rates. The log rank test was used for survival comparison and univariate prognostic analysis. The Cox model was used for multivariate prognostic analysis. The median follow-up time was 102.6 months. The median survival time, 2- and 5-year overall survival (OS) were 22.7 months, 49.9% and 28.3%. The median, 2- and 5-year progression-free survival were 12.6 months, 35.8% and 25.8%. The 2- and 5-year locoregional recurrence-free survival were 59.1% and 50.8%. The 2- and 5-year distant metastases-free survival were 74.6% and 65.9%. Multivariate analysis showed that EQD(2)>66 Gy was the only independent prognostic indicator for OS (=0.040). The median survival time and 5-year OS rate significantly improved in patients who received EQD(2)>66 Gy than those who received≤66 Gy (31.2 months vs. 19.2 months, 40.1% vs. 19.1%, =0.027). A total of 87 patients (58.8%) developed tumor progression. There were 50 (33.8%), 23 (15.5%) and 39 (26.4%) patients developed local, regional recurrence and distant metastases, respectively. Eleven patients (7.4%) underwent salvage surgery, and the laryngeal preservation rate for entire group was 93.9%. Definitive radiotherapy is an effective treatment for cervical esophageal carcinoma with the advantage of larynx preservation. Local recurrence is the major failure pattern. EQD(2)>66 Gy is associated with the improved overall survival.
评估颈段食管癌(CEC)患者根治性放疗的长期疗效、失败模式及预后因素。我们回顾性分析了2001年1月至2017年12月在中国医学科学院肿瘤医院接受根治性放疗的148例CEC患者的临床资料。中位放疗剂量为66 Gy(59.4 - 70 Gy),33.1%的患者接受了同步化疗。采用Kaplan-Meier法计算生存率。采用对数秩检验进行生存比较和单因素预后分析。采用Cox模型进行多因素预后分析。中位随访时间为102.6个月。中位生存时间、2年和5年总生存率(OS)分别为22.7个月、49.9%和28.3%。中位、2年和5年无进展生存率分别为12.6个月、35.8%和25.8%。2年和5年局部区域无复发生存率分别为59.1%和50.8%。2年和5年远处转移无复发生存率分别为74.6%和65.9%。多因素分析显示,等效剂量(2)>66 Gy是OS的唯一独立预后指标(P = 0.040)。接受等效剂量(2)>66 Gy的患者中位生存时间和5年OS率显著高于接受等效剂量(2)≤66 Gy的患者(31.2个月对19.2个月,40.1%对19.1%,P = 0.027)。共有87例患者(58.8%)出现肿瘤进展。分别有50例(33.8%)、23例(15.5%)和39例(26.4%)患者出现局部、区域复发和远处转移。11例患者(7.4%)接受了挽救性手术,全组喉保留率为93.9%。根治性放疗是治疗颈段食管癌的有效方法,具有保留喉功能的优势。局部复发是主要的失败模式。等效剂量(2)>66 Gy与总生存改善相关。